Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Myasthenia Gravis 4

Interventions

Cisplatin 187Carboplatin 182Paclitaxel 177Docetaxel 145Cyclophosphamide 129Dexamethasone 117pembrolizumab 106Doxorubicin 103Bevacizumab 103Gemcitabine 102Rituximab 96Prednisone 87Fluorouracil 86Pemetrexed 82Radiotherapy 77Vincristine 71Etoposide 71Capecitabine 69Nivolumab 68Trastuzumab 67Leucovorin 64Cytarabine 57Methotrexate 52Oxaliplatin 49atezolizumab 48Lenalidomide 43Ipilimumab 40Filgrastim 40Bortezomib 39Sorafenib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Has results × rozanolixizumab × Clear all
NCT03971422 2025-12-24

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
200 enrolled 20 charts

Myasthenia Gravis

NCT05681715 2025-11-06

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

UCB Pharma

Phase 3 Completed
62 enrolled 11 charts

Myasthenia Gravis

NCT04650854 2025-04-18

A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
165 enrolled 21 charts

Myasthenia Gravis

NCT04124965 2023-09-05

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
71 enrolled 15 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡